For Better user experience please view the website in portrait Mode

Atul Sharan President and Chief Executive Officer

Atul Sharan founded CellMax Life while an Entrepreneur-in-Residence at Artiman Ventures. Prior to CellMax, Atul was President and CEO at AutoESL (acquired by Xilinx), Founder, President and CEO at Clear Shape Technologies (acquired by Cadence), and held a variety of senior leadership positions in the EDA field. Atul has an M.B.A. from UC-Berkeley in Finance & Management, an M.S. in Engineering from the University of Houston and a B.S. in Engineering from IIT, Kanpur.

CellMax Life

CellMax Life, Inc. is a precision cancer blood-testing company providing comprehensive, personalized multi-biomarker technology platforms for genetic cancer risk assessment, early detection and personalized treatment of cancer. 

Amit ShahPartner

Currently on the boards of Adama Materials, Aditazz, Auryn, CellMax Life, Guavus, Kaybus, Niron Magnetics and InvenSense. Amit Shah is peerless in creating globally renowned businesses. A successful serial entrepreneur, Amit founded two companies Zeitnet (acquired by Cabletron) and PipeLinks (acquired by Cisco) before founding Artiman Ventures. Over the years, he has led investments in companies such as Everest Design Automation (acquired by Synopsys), IKANOS (Nasdaq: IKAN), iManage (Nasdaq: IMAN), Lightwire (acquired by Cisco Systems), Netscaler (acquired by Citrix), Sierra Design Automation (acquired by Mentor Graphics), Tavant (acquired by Ameriquest).

Akhil Saklecha Partner

With over 15 years of experience in medicine and healthcare management, Akhil Saklecha has a strong inclination towards medical technology. As a partner at Artiman, Akhil focuses on early-stage investments and has led investments in CellMax Life, DMS Networks and HomeUnion. Board certified in Emergency Medicine, Akhil is an assistant professor at Northeast Ohio Medical University and a Fellow of the American College of Emergency Medicine.

Colorectal Cancer Diagnosis

Cancer Risk Assessment

Remission Monitoring

Precision Treatment